Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
KalVista Pharmaceuticals
AddedFeb 19, 2024
UpdatedJun 18, 2026
KalVista Pharmaceuticals

KalVista Pharmaceuticals

Acquired

KalVista Pharmaceuticals develops and commercializes protease inhibitors for unmet medical needs in the US and UK.

HQ
Cambridge, MA, US
Founded
2004
Overview
Compare
Fundraising
Employees
Website

KalVista Pharmaceuticals, founded with a mission to address significant unmet medical needs, focuses on the discovery, development, and commercialization of small molecule protease inhibitors. The company's primary market is the United States and the United Kingdom, where it aims to transform the treatment landscape for hereditary angioedema (HAE) through innovative, orally-delivered medicines. KalVista is committed to empowering individuals to live beyond the challenges of their diseases.

Notable affiliated individuals include experienced scientists and industry leaders who drive the company's research and development efforts. KalVista has secured investments from prominent venture capital firms, bolstering its financial stability and growth potential. Key achievements include advancing several promising candidates in clinical trials, positioning the company as a leader in HAE treatment innovation. The overall impact of KalVista Pharmaceuticals lies in its potential to significantly improve the quality of life for patients with HAE through groundbreaking therapeutic options.

KalVista Pharmaceuticals - Similar Companies

Rigel Pharmaceuticals logo

Rigel Pharmaceuticals

rigel.com

Gilead Sciences logo

Gilead Sciences

gilead.com

PTC Therapeutics logo

PTC Therapeutics

ptcbio.com

AstraZeneca logo

AstraZeneca

astrazeneca.com

KALA BIO logo

KALA BIO

kalarx.com

Variant Pharmaceuticals logo

Variant Pharmaceuticals

variantpharma.com

Enanta Pharmaceuticals logo

Enanta Pharmaceuticals

enanta.com

Karyopharm Therapeutics logo

Karyopharm Therapeutics

karyopharm.com

Astria Therapeutics logo

Astria Therapeutics

astriatx.com

United Therapeutics logo

United Therapeutics

Valcrest Pharmaceuticals logo

Valcrest Pharmaceuticals

BioCryst Pharmaceuticals logo

BioCryst Pharmaceuticals

biocryst.com

Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

kiniksa.com

Osprey Pharmaceuticals USA logo

Osprey Pharmaceuticals USA

ospreypharma.com

Vertice Pharma logo

Vertice Pharma

KalVista Pharmaceuticals - Quick Facts

Who are KalVista Pharmaceuticals' competitors?

Companies similar to KalVista Pharmaceuticals include Rigel Pharmaceuticals, Gilead Sciences, PTC Therapeutics and AstraZeneca.

When was KalVista Pharmaceuticals founded?

KalVista Pharmaceuticals was founded in 2004.

Where is KalVista Pharmaceuticals' headquarters located?

KalVista Pharmaceuticals' headquarters is located in Cambridge, MA, US.

When was KalVista Pharmaceuticals' last funding round?

KalVista Pharmaceuticals' most recent funding round was for $58M (USD) in December 2022.

How much has KalVista Pharmaceuticals raised to-date?

As of Dec 27, 2022, KalVista Pharmaceuticals has raised a total of $292.5M (USD).

KalVista Pharmaceuticals - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 15 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 4772Retail sale of pharmaceutical and medical goods, cosmetic and toilet articles in specialized stores